1 Min Read
April 18 (Reuters) - Cerenis Therapeutics Holding SA:
* Announces initiation of Phase 1 clinical study with CER-209 in NAFLD and NASH Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.